Keith Osterhage has been appointed executive director of Marquette University’s Office of Research and Sponsored Programs, effective Nov. 3. Osterhage succeeds Erik Thelen, who resigned at the end of the 2007-08 academic year.
Osterhage formerly served as the director of the Office of Research and Sponsored Programs at Rutgers University, where he managed a staff of 20 and oversaw the distribution of awards totaling more than $295 million in a single year. He has also worked in the research offices at Georgetown University and American University, and as an independent consultant.
Osterhage holds master’s degrees in political science and public administration from Ohio State University, and a bachelor’s degree in history and political science from Northern Ohio University.
The California Healthcare Institute said this week that Michael Friedman, president and chief executive officer of City of Hope, was elected to the CHI board of directors.
Prior to joining City of Hope, Friedman was senior vice president of research and development, medical and public policy, for Pharmacia Corporation. In addition, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America following the events of Sept. 11, 2001.
Friedman has also previously served as US Food and Drug Administration deputy commissioner and acting commissioner; and was associate director of the Cancer Therapy Evaluation Program in the Division of Cancer Treatment at the National Cancer Institute. Friedman also spent nearly a decade at the University of California at San Francisco, serving as associate professor of medicine, and interim director of the Cancer Research Institute.
He received his bachelor’s degree from Tulane University and MD from the University of Texas. He completed postdoctoral training at Stanford University and the NCI.
CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics, and pharmaceutical firms.